Wang Bei, Xu Jin-Shui, Wang Chang-Xian, Mi Zu-Huang, Pu Yue-Pu, Hui Mamie, Ling Thomas K W, Chan Chiu-Yeung
School of Public Health, Southeast University, Nanjing, Jiangsu, People's Republic of China.
Wuxi Clon-Gen Technique Institute, Wuxi, Jiangsu, People's Republic of China.
J Med Microbiol. 2006 Sep;55(Pt 9):1251-1255. doi: 10.1099/jmm.0.46401-0.
In this study, the phenotypic and genotypic resistance to fluoroquinolones in Neisseria gonorrhoeae isolated in Jiangsu Province, China, was analysed. In vitro susceptibility testing of eight antimicrobial agents, including ciprofloxacin and levofloxacin, against 95 clinical isolates was carried out. Detection of mutations in the gyrA and parC genes was performed by sequence analysis. The clinical isolates demonstrated 100% resistance to ciprofloxacin and 98.9% non-susceptibility to levofloxacin. All of the isolates were susceptible to cefotaxime and ceftriaxone. For cefepime, spectinomycin and tetracycline, 98.9, 94.7 and 1.1% of the isolates were susceptible, respectively. None of the isolates was susceptible to penicillin. Five types based on gyrA mutations could be categorized among 54 isolates with seven different mutation sites found on their parC gene. Analysis of sequence results showed that the gyrA mutation Asp-95-->Ala and the parC mutations Ser-87-->Arg and Ser-87-->Asn made a significant contribution to the resistance to fluoroquinolones, in addition to double mutations found in each gene. Therefore, the use of fluoroquinolones in the treatment of N. gonorrhoeae infections in Jiangsu Province is not recommended, while the use of third- and fourth-generation cephalosporins and spectinomycin is recommended.
本研究分析了中国江苏省分离出的淋病奈瑟菌对氟喹诺酮类药物的表型和基因型耐药性。对包括环丙沙星和左氧氟沙星在内的8种抗菌药物对95株临床分离株进行了体外药敏试验。通过序列分析检测gyrA和parC基因中的突变。临床分离株对环丙沙星的耐药率为100%,对左氧氟沙星的不敏感率为98.9%。所有分离株对头孢噻肟和头孢曲松敏感。对于头孢吡肟、大观霉素和四环素,分离株的敏感率分别为98.9%、94.7%和1.1%。没有分离株对青霉素敏感。在54株分离株中可根据gyrA突变分为5种类型,在其parC基因上发现了7个不同的突变位点。序列结果分析表明,除了每个基因中发现的双突变外,gyrA突变Asp-95→Ala以及parC突变Ser-87→Arg和Ser-87→Asn对氟喹诺酮类药物耐药性有显著贡献。因此,不建议在江苏省使用氟喹诺酮类药物治疗淋病奈瑟菌感染,而建议使用第三代和第四代头孢菌素以及大观霉素。